Biocompatibles settles DOJ marketing probe

A subsidiary of London-based BTG, Biocompatibles reached a settlement with the U.S. Department of Justice over marketing of its interventional medicine brand. 

By Joe Cantlupe • Oct. 12, 2016

Allergan launches #ActuallySheCan mentorship for women

The specialty pharma is showcasing successful women to show that actually she can. 

By Suzanne Elvidge • Oct. 12, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

AHA: Inpatient drug costs skyrocketing

Hospital drugs costs shot up by almost 40% between 2013 and 2015, according to the hospital association's survey.

By Suzanne Elvidge • Oct. 12, 2016

Shire wants consumers and their eyes to be 'Friends'

On the heels of its first approval in ophthalmics, Shire is conducting an all-fronts drive to educate patients about dry eye, including a cameo from Jennifer Aniston. 

By Lisa LaMotta • Oct. 11, 2016

Merck inks pay-for-performance deal to boost diabetes drugs

Under an agreement with Aetna, rebates for Januvia and Janumet will be tied to treatment outcomes among type 2 diabetes patients. 

By Ned Pagliarulo • Oct. 11, 2016

Downfall of a unicorn: How Theranos fell apart

Elizabeth Holmes' decision to close down Theranos' clinical labs represents a marked retreat from her original aim to transform the blood-testing business. 

By Ned Pagliarulo • Oct. 10, 2016

Major US insurer snubs Sarepta's Duchenne drug

Anthem, one of the largest health insurers in the U.S., said it would not cover Exondys 51, which was controversially approved by the FDA last month. 

By Ned Pagliarulo • Oct. 9, 2016

Celltrion finds new partner after Pfizer exit

The partnership is the latest in a string of biosimilar marketing and production pacts that have popped up in the last few years.

By Jacob Bell • Oct. 6, 2016

FDA adds boxed warning to hepatitis C drugs

The regulator cited two deaths and 24 adverse events related to hepatitis B reactivations among patients treated with new direct-acting antivirals.

By Joe Cantlupe • Oct. 5, 2016

New anti-PD1 drugs overpriced, ICER says

The research group's efforts to put a value on new drugs has sparked backlash from the pharma industry in recent months. 

By Suzanne Elvidge • Oct. 5, 2016

CytoSorbents pushes into European cardiac market

The New Jersey-based company makes a device designed to reduce inflammatory responses such as a "cytokine storm." 

By Suzanne Elvidge • Oct. 5, 2016

NCPA wants congress to examine PBM role in EpiPen pricing

The National Community Pharmacists Association calls for a congressional committee to examine pharmacy benefit managers' role in the EpiPen and other drug pricing fiascoes.

By Joe Cantlupe • Oct. 4, 2016

PhRMA continues critique of drug pricing studies

The major pharma trade association, along with several drugmakers, has pushed back against ICER's attempts to measure drug value. 

By Joe Cantlupe • Sept. 29, 2016

Athenex and SunGen seal deal for US market

The joint venture, which has the companies working together to launch and market seven drugs, is one of several it has planned for the near term.

By Joe Cantlupe • Sept. 28, 2016

UK cancer charity builds on awareness efforts

Cancer Research UK is launching its first massive open online course to improve early cancer diagnosis and help health professionals discuss the disease. 

By Suzanne Elvidge • Sept. 28, 2016

ADA steps out with #DiabetesDanceDare

Taking the success of The ALS Association's Ice Bucket Challenge to heart, the American Diabetes Association is launching a new social media campaign to raise donations. 

By Suzanne Elvidge • Sept. 28, 2016

Mylan CEO Bresch grilled by Congress over EpiPen

Bresch's showdown with the House Oversight Committee bore some similarities to hearings earlier this year criticizing CEOs from Valeant and Turing over high drug prices. 

By Suzanne Elvidge • Sept. 22, 2016

IMS Health: PBMs lower hep C costs for US

Pharmacy benefit managers touted a report showing hepatitis C drug costs were lower in the U.S. than in other countries, ostensibly due to their tough negotiating. 

By Joe Cantlupe • Sept. 21, 2016

BIO: Concerns about orphan drug costs 'misguided'

The industry organization defended the Orphan Drug Act against further backlash. 

By Joe Cantlupe • Sept. 21, 2016

Sarepta names that price

The rare disease biotech gave details about pricing and manufacturing for its newly-approved DMD drug in a call with analysts Monday. 

By Lisa LaMotta • Sept. 20, 2016

Valeant: rebates on heart drugs are coming

The drugmaker responded to a report that it has not delivered on promised discounts for drugs. 

By Ned Pagliarulo • Sept. 19, 2016

BIO blames insurers in pushback on drug pricing

Continuing its aggressive defense of the biotech industry, BIO unveiled a new microsite attacking insurers for driving up drug costs. 

By Ned Pagliarulo • Sept. 14, 2016

WellDoc, LifeScan join forces on digital diabetes partnership

The collaboration is aimed at improving care management for people with type 2 diabetes. 

By Suzanne Elvidge • Sept. 14, 2016

Express Scripts creates value pricing model for RA drugs

The care program could cut costs for patients and encourage better care, but will limit payments to pharma.

By Suzanne Elvidge • Sept. 12, 2016

Pfizer's Read suggests need for better transparency on pricing

The high-profile CEO pointed to broader problems within the current healthcare system at an investor conference. 

By Lisa LaMotta • Sept. 9, 2016